THE BEST SIDE OF MOUNJARO

The trial realized the two its Most important endpoints, with semaglutide 2.four mg demonstrating statistically considerable and top-quality improvements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis without having worsening of liver fibrosis in individuals with MASH in comparison to placebo.o